Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SV2E
|
|||
| Drug Name |
PMID26161698-Compound-32
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
LEAD DISCOVERY CENTER GMBH MAX-PLANCK-GESELLSCHAFT ZUR FDERUNG DER WISSENSCHAFTEN E.V. CHOIDAS, Axel KLEBL, Bert HABENBERGER, Peter EICKHOFF, Jan THOMAS, Roman HEUCKMANN, Johannes
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H17N5O3S
|
|||
| Canonical SMILES |
COC1=CC=CC=C1C2=NC(=NC=N2)NC3=CC=CC(=C3)CS(=O)(=O)N
|
|||
| InChI |
1S/C17H17N5O3S/c1-25-15-8-3-2-7-14(15)16-19-11-20-17(22-16)21-13-6-4-5-12(9-13)10-26(18,23)24/h2-9,11H,10H2,1H3,(H2,18,23,24)(H,19,20,21,22)
|
|||
| InChIKey |
BQJUSTFHSZCQFK-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclin-dependent kinase 9 (CDK9) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Cyclin-dependent kinase 9 (CDK9) | Target's Patent Info | [1] | |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| Reactome | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | |||
| WikiPathways | Cardiac Hypertrophic Response | |||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
| Host Interactions of HIV factors | ||||
| HIV Life Cycle | ||||
| IL-9 Signaling Pathway | ||||
| RNA Polymerase II Transcription | ||||
| MicroRNAs in cardiomyocyte hypertrophy | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.